et al. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (pi3k) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist 21, 787–788 (2016). Article CAS PubMed PubMed Central Google Scholar Lukey, P. T. et al....
& Cao, X. Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-κB activation. Mol. Immunol. 45, 2929–2936 (2008). Article CAS PubMed Google Scholar Tanabe, H. et al. Mouse Paneth cell secretory responses to cell ...
SCs play a crucial role in providing nutritional support to GCs via a mTOR mechanism. Rapamycin (mTOR inhibitor) can alter several metabolic parameters, including glucose consumption and mitochondrial complex III protein levels in human SCs30. mTOR dysregulation has also been associated with the onset...
-In trained individuals, a large amount of fat oxidation takes place at intensities well above 80% VO2max – giving an athlete the ability to get up to even very higher intensity efforts without having drained their carbohydrate stores getting up to that point, and also allowing athletes engagi...
Interestingly, rapid development of the atrophic process in mouse soleus during three-day hindlimb immobilization can be prevented by rapamycin [44] and sestrin overexpression [59], which leads to a decrease in the level of p70S6K phosphorylation. This anti-atrophic effect of m...
DAMP: Damage-associated molecular pattern HMGB1: High mobility group box protein 1 Keap1: Kelch-like ECH-associated protein 1 MDSC: Myeloid-derived suppressor cells Monocytic MDSC mTOR: Mammalian target of rapamycin Nrf2: Nuclear factor erythroid-2-related factor 2 ...
N. Rapamycin. (AY-22,989), a new antifungal antibiotic. I. Taxomony of the producing streptomycete and isolation of the active principle. J. Antibiot. 10, 721–726 (1975). Article Google Scholar Richon, V. M. et al. Second generation hybrid polar compounds are potent inducers of ...
Some antibodies and small-molecule inhibitors against FGFR are currently in clinical testing, such as TKI-259 single agent, and Exemestane [27]. Agents targeting the PI3K pathway comprise rapamycin analogues or mTOR inhibitors [27]. The basal-like subtype, one of the most clinically aggressive gro...
Mutations in these genes disrupt this complex, leading to abnormal cellular signaling, cell proliferation, and fluid secretion, all of which contribute to the formation and growth of renal cysts. Key molecular pathways implicated in ADPKD pathogenesis include the mammalian target of rapamycin (mTOR),...